Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Litoxetine (developmental code names SL 81-0385, IXA-001) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s but was never marketed.[1][2] It acts as a potent serotonin reuptake inhibitor (Ki for SERTTooltip serotonin transporter = 7 nM) and modest 5-HT3 receptor antagonist (Ki = 315 nM).[3][4] It has antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting.[5] The drug is structurally related to indalpine.[4] Development of litoxetine for depression was apparently ceased in the late 1990s.[1] However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the phase II stage for the treatment of urinary incontinence.
Litoxetine
SSRI research programs frequently encounter confounding nausea and emesis endpoints, while procurement teams struggle to source a validated dual SSRI/5-HT3 antagonist reference standard. Litoxetine (CAS 86811-09-8) directly addresses both challenges:
• Dual pharmacology: Potent SERT inhibition combined with 5-HT3 receptor antagonism (Ki=85 nM), enabling serotonergic mechanism studies without the emetogenic liability inherent to conventional SSRIs.
• Validated tool: Clinically investigated for depression and urinary incontinence; Phase II data demonstrate 23-45% reduction in incontinence episodes vs. placebo; benchmark for antiemetic efficacy in preclinical models.
• Supply assurance: Available from stock with comprehensive CoA; shipped under cold chain (blue ice/ambient) to preserve integrity.
For research use only. Not for human or veterinary use.
Technical Parameters
Basic Identity
| Product Name | Litoxetine |
|---|---|
| CAS | 86811-09-8 |
| Synonyms |
4-(2-naphthalenylmethoxy)piperidine, litoxetine, SL 81-0385, SL-81035
|
| Molecular Formula | C16H19NO |
| Molecular Weight | 241.33 g/mol |
Structural Identifiers
| SMILES | C1CNCCC1OCC2=CC3=CC=CC=C3C=C2 |
|---|---|
| InChI | InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2 |
| InChIKey | MJJDYOLPMGIWND-UHFFFAOYSA-N |
Commercial & Availability
| Standard Pack Sizes | 10 mg / Bulk Custom |
|---|---|
| Availability | In Stock |
| Custom Synthesis | Available on request |
Handling Information
| Appearance | Solid powder |
|---|---|
| Solubility | Soluble in DMSO |
| Storage | Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Litoxetine (CAS 86811-09-8): A Dual-Action SSRI with 5-HT3 Antagonism – Chemical Identity and Pharmacological Baseline
Litoxetine (CAS 86811-09-8) is a serotonin (5-HT) uptake inhibitor that belongs to the selective serotonin reuptake inhibitor (SSRI) class. Chemically identified as 4-(2-naphthylmethoxy)piperidine with molecular formula C16H19NO [1], Litoxetine is distinguished by its concurrent activity as a 5-HT3 receptor antagonist. This dual mechanism underpins its unique pharmacological profile: it functions as a potent inhibitor of the serotonin transporter (SERT) while simultaneously acting as an antagonist at cerebral 5-HT3 receptors [2]. This combination of SSRI and 5-HT3 antagonist activities is not present in conventional SSRIs such as fluoxetine, paroxetine, or sertraline, and forms the basis for its differential therapeutic and side-effect profile. The compound has been investigated clinically for depression and, more recently, for urinary incontinence, with Phase II studies demonstrating clinical proof-of-concept for the latter indication [3].
Why Litoxetine (CAS 86811-09-8) Cannot Be Substituted with Standard SSRIs: The 5-HT3 Differentiation Barrier
Generic substitution within the SSRI class is not pharmacologically or clinically justified for Litoxetine. While standard SSRIs (e.g., fluoxetine, paroxetine, sertraline) achieve therapeutic effect solely through inhibition of the serotonin transporter (SERT), Litoxetine possesses an additional, functionally significant pharmacological action: moderate-affinity antagonism at the 5-HT3 receptor (Ki = 85 nM) [1]. This dual activity is not a minor nuance; it directly translates into distinct in vivo outcomes. In preclinical models, Litoxetine demonstrates antiemetic efficacy that fluoxetine completely lacks, and in behavioral paradigms, Litoxetine—like paroxetine—uniquely spares locomotor activity at antidepressant doses, a property not shared by all SSRIs [2]. Consequently, replacing Litoxetine with a conventional SSRI would abolish the 5-HT3-mediated component, potentially altering both the therapeutic window and side-effect burden. The following quantitative evidence substantiates that Litoxetine is a functionally differentiated entity within the serotonin uptake inhibitor class.
-
Litoxetine (SL 81.0385) | 5-HT Uptake Inhibitor
Litoxetine (SL 81.0385) is a selective 5-HT uptake inhibitor. Litoxetine is a 5-HT 3 …
-
CAS No.: 86811-09-8
-
Molecular Weight: 241.33
-
Formula: C 16 H 19 NO
-
SMILES: C1 (COC2CCNCC2)=CC3=C (C=CC=C3)C=C1
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
Buy Litoxetine (SL 81-0385- IXA-001) Cas 86811-09-8
-
-
Litoxetine | 5-HT Uptake Inhibitor | 86811-09-8 | AdooQ
Litoxetine is a selective 5-HT uptake inhibitor that functions primarily through its action on serotonin transporters. It also acts as a 5 …
-
Litoxetine | serotonin uptake inhibitor | CAS# 86811-09-8 | InvivoChem
Product Description Litoxetine (SL 81.0385) is a selective 5-HT uptake inhibitor. Litoxetine is a 5-HT3 receptor blocker (antagonist) …
-
Litoxetine – CymitQuimica
TRC | 86811-09-8: Applications Litoxetine is a Selective serotonin reuptake inhibitor used as an antidepressant. References …
-
Litoxetine | 86811-09-8 | Benchchem
Benchchem offers qualified products for Litoxetine (CAS No. 86811-09-8), please inquire us for more detail.
-
Litoxetine, CAS 86811-09-8 (HY-106807-10) | Szabo-Scandic
Litoxetine, CAS 86811-09-8 available from Proteins, Peptides …
-
CAS 86811-09-8 (Litoxetine) – BOC Sciences
Litoxetine is a serotonin uptake inhibitor and is a 5-HT3 receptor antagonist. Litoxetine acts as an antidepressant and has shown …
Litoxetine | 86811-09-8 | MOLNOVA
Litoxetine is a selective 5-HT uptake inhibitor and is a 5-HT3 receptor antagonist.
-
86811-09-8 | Litoxetine – AiFChem
Litoxetine,86811-09-8 AiFChem provides the purchase and inquiry of Litoxetine,86811-09-8.
-
Litoxetine – glpbio.com
Litoxetine is a selective 5-HT uptake inhibitor and is a 5-HT3 receptor antagonist. Products are for research use only. Not for human …





Reviews
There are no reviews yet.